Recently, an anti-IL-2R IT containing dgRTA has been approved by the US Food and Drug Administration for the treatment of cutaneous T-cell lymphoma in adults [13,53]. The gene discussed is IL2RA; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.